Human immunodeficiency virus type 1 (HIV-1) virion (HIV-1 virion)

Extracellular HIV-1 virions and other pathogens refer to the infectious, cell-free particles of viruses and bacteria that circulate within the host's bloodstream and interstitial fluids. These entities are the primary vehicles for systemic dissemination and are characterized by complex structural features, such as the lipid envelope and surface glycoproteins in the case of HIV-1 [1]. The surface of an HIV-1 virion is notably studded with gp120 and gp41 glycoproteins, which are essential for binding to host cell receptors like CD4 and CCR5 [2]. Therapeutic targeting of these extracellular particles aims to reduce the overall "pathogen burden" or "viral load" to prevent new cellular infections and mitigate systemic inflammation. This is often achieved through extracorporeal affinity-capture technologies, such as the Hemopurifier, which utilizes lectins like Galanthus nivalis agglutinin to physically remove glycosylated pathogens from the blood [3, 4]. While this approach can rapidly decrease circulating levels of the pathogen, it is typically used as an adjunct to systemic therapies that address intracellular reservoirs [5].

Other names

Non-specific extracellular HIV-1 virions and other pathogensHuman immunodeficiency virus type 1 particleCirculating HIV-1 virionExtracellular pathogensGlycosylated viral particles

Physical removal of glycosylated viral particles and toxins from the circulatory system via lectin-affinity chromatography [3, 4].